|
1
|
Lynch HT and de la Chapelle A: Hereditary
colorectal cancer. N Engl J Med. 348:919–932. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wells K and Wise PE: Hereditary colorectal
cancer syndromes. Surg Clin North Am. 97:605–625. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lynch HT, Kimberling W, Albano WA, Lynch
JF, Biscone K, Schuelke GS, Sandberg AA, Lipkin M, Deschner EE,
Mikol YB, et al: Hereditary nonpolyposis colorectal cancer (lynch
syndrome I and II). I. Clinical description of resource. Cancer.
56:934–938. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bandipalliam P: Syndrome of early onset
colon cancers, hematologic malignancies & features of
neurofibromatosis in HNPCC families with homozygous mismatch repair
gene mutations. Fam Cancer. 4:323–333. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the world health organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Churpek JE, Marquez R, Neistadt B,
Claussen K, Lee MK, Churpek MM, Huo D, Weiner H, Bannerjee M,
Godley LA, et al: Inherited mutations in cancer susceptibility
genes are common among survivors of breast cancer who develop
therapy-related leukemia. Cancer. 122:304–311. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Larson RA: Etiology and management of
therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ
Program. 1–459. 2007.PubMed/NCBI
|
|
8
|
Pedersen-Bjergaard J, Andersen MT and
Andersen MK: Genetic pathways in the pathogenesis of
therapy-related myelodysplasia and acute myeloid leukemia.
Hematology Am Soc Hematol Educ Program. 1–397. 2007.PubMed/NCBI
|
|
9
|
Haase D: Cytogenetic features in
myelodysplastic syndromes. Ann Hematol. 87:515–526. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Godley LA and Larson RA: Therapy-related
myeloid leukemia. Semin Oncol. 35:418–429. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park HJ, Choi JH, Lee KA, Kim HC, Nam YS,
Oh YH and Lee WS: A case of therapy-related acute myeloid leukemia
following 5-fluorouracil chemotherapy. Korean J Intern Med.
27:115–117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hangaishi A, Ogawa S, Mitani K, Hosoya N,
Chiba S, Yazaki Y and Hirai H: Mutations and loss of expression of
a mismatch repair gene, hMLH1, in leukemia and lymphoma cell lines.
Blood. 89:1740–1747. 1997.PubMed/NCBI
|
|
13
|
Maeck L, Haase D, Schoch C, Hiddemann W
and Alves F: Genetic instability in myelodysplastic syndrome:
Detection of microsatellite instability and loss of heterozygosity
in bone marrow samples with karyotype alterations. Br J Haematol.
109:842–846. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hou HA, Kuo YY, Tang JL, Chou WC, Yao M,
Lai YJ, Lin CC, Chen CY, Liu CY, Tseng MH, et al: Clinical
implications of the SETBP1 mutation in patients with primary
myelodysplastic syndrome and its stability during disease
progression. Am J Hematol. 89:181–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fabiani E, Falconi G, Fianchi L, Criscuolo
M, Leone G and Voso MT: SETBP1 mutations in 106 patients with
therapy-related myeloid neoplasms. Haematologica. 99:e152–e153.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Evans DG, Bowers N, Burkitt-Wright E,
Miles E, Garg S, Scott-Kitching V, Penman-Splitt M, Dobbie A,
Howard E, Ealing J, et al: Comprehensive RNA analysis of the NF1
gene in classically affected NF1 affected individuals meeting NIH
criteria has high sensitivity and mutation negative testing is
reassuring in isolated cases with pigmentary features only.
EBioMedicine. 7:212–220. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Haase D, Germing U, Schanz J, Pfeilstöcker
M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R,
Giagounidis AA, et al: New insights into the prognostic impact of
the karyotype in MDS and correlation with subtypes: Evidence from a
core dataset of 2124 patients. Blood. 110:4385–4395. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Allan JM, Wild CP, Rollinson S, Willett
EV, Moorman AV, Dovey GJ, Roddam PL, Roman E, Cartwright RA and
Morgan GJ: Polymorphism in glutathione S-transferase P1 is
associated with susceptibility to chemotherapy-induced leukemia.
Proc Natl Acad Sci USA. 98:pp. 11592–11597. 2001; View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Larson RA, Wang Y, Banerjee M, Wiemels J,
Hartford C, Le Beau MM and Smith MT: Prevalence of the inactivating
609C->T polymorphism in the NAD(P)H:quinone oxidoreductase
(NQO1) gene in patients with primary and therapy-related myeloid
leukemia. Blood. 94:803–807. 1999.PubMed/NCBI
|
